| First Author | Rabbitts TH | Year | 2001 |
| Journal | Oncogene | Volume | 20 |
| Issue | 40 | Pages | 5763-77 |
| PubMed ID | 11607826 | Mgi Jnum | J:72274 |
| Mgi Id | MGI:2152238 | Doi | 10.1038/sj.onc.1204597 |
| Citation | Rabbitts TH (2001) Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene 20(40):5763-77 |
| abstractText | Molecular biologists have elucidated general principles about chromosomal translocations by cloning oncogenes or fusion genes at chromosomal translocation junctions. These genes invariably encode intracellular proteins and in acute cancers, often involve transcription and developmental regulators, which are master regulators of cell fate (e.g. LMO2 which is involved in acute leukaemia). Chromosomal translocations are usually associated with specific cell types. The reason for this close association is under investigation using mouse models. We are trying to emulate the cell-specific consequences of chromosomal translocations in mice using homologous recombination in embryonic stem cells to generate de novo chromosomal translocations or to mimic the consequence of these translocations. In addition, chromosomal translocation genes and their products are important targets for therapy. We have designed new therapeutic strategies which include antigen-specific recruitment of endogenous cellular pathways to affect cellular viability and a novel structured form of antisense to ablate the function of fusion mRNAs. We will evaluate these procedures in the mouse models of chromosomal translocations and the long term aim is to perfect rapid procedures for characterizing patient-specific chromosomal translocations to tailor therapy to individual patients. |
